NEW YORK – Meilleur Technologies on Tuesday said the Young Blood Institute will use its investigational PET imaging agent [F-18]NAV-4694 to measure beta-amyloid in the brain as part of the institute's Amyloid βeta Assessment & Removal Intervention (AmβARI) study.
In the AmβARI study, investigators from the Young Blood Institute are testing plasma exchange therapy and whether it can prevent Alzheimer's disease by removing beta-amyloid. As part of the study, investigators will use the [F-18]NAV-4694 tracer as an imaging biomarker to detect and monitor beta-amyloid, a hallmark sign of Alzheimer's disease.
The Young Blood Institute is a nonprofit research group studying plasma exchange therapies and their potential to slow aging, a process that the US Food and Drug Administration previously has raised concerns about and cautioned patients about participating in.
The principal investigator on the trial is Colin Masters, a professor of dementia research at the University of Melbourne in Australia. Investigators will use mass spectrometry blood tests to screen subjects for beta-amyloid as part of the study, and PET imaging will be used by investigators to confirm diagnosis, said Mark Urdahl, the Young Blood Institute's president and CEO.
Meilleur Technologies has struck multiple deals in recent months to use [F-18]NAV-4694 in research, including within the Alzheimer's Disease Neuroimaging Initiative 4 study and the Consortium for Clarity in ADRD Research Through Imaging study.